

Ocata Therapeutics, Inc.  
Form 8-K  
August 06, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **August 6, 2015**

**OCATA THERAPEUTICS, INC.**  
(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b>	<b>000-50295</b>	<b>87-0656515</b>
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

<b>33 Locke Drive, Marlborough, Massachusetts 01752</b>	
(Address of Principal Executive Offices)	(Zip Code)

Edgar Filing: Ocata Therapeutics, Inc. - Form 8-K

Registrant's Telephone Number, Including Area Code: **(508) 756-1212**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On August 6, 2015, Ocata Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2015 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.

*The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.*

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
----------------	-------------

99.1	Press Release, dated August 6, 2015
------	-------------------------------------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ocata Therapeutics, Inc.**

Date: August 6, 2015 By: /s/ Edward Myles  
Edward Myles  
Chief Financial Officer and Chief Operating Officer